These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22028352)

  • 21. Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel.
    Kleiman NS
    JACC Cardiovasc Interv; 2008 Dec; 1(6):628-30. PubMed ID: 19463376
    [No Abstract]   [Full Text] [Related]  

  • 22. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
    Bonello-Palot N; Armero S; Paganelli F; Mancini J; De Labriolle A; Bonello C; Lévy N; Maillard L; Barragan P; Dignat-George F; Camoin-Jau L; Bonello L
    Am J Cardiol; 2009 Dec; 104(11):1511-5. PubMed ID: 19932784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].
    Tang XF; He C; Yuan JQ; Meng XM; Yang YJ; Qin XW; Qiao SB; Liu HB; Wu YJ; Yao M; Chen J; You SJ; Wu Y; Li JJ; Dai J; Chen JL; Gao RL; Chen ZJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jul; 39(7):617-20. PubMed ID: 22088240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Am J Cardiol; 2009 Mar; 103(6):806-11. PubMed ID: 19268736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
    Tavassoli N; Voisin S; Carrie D; Lapeyre-Mestre M; Galinier M; Montastruc JL; Pathak A
    Am J Cardiovasc Drugs; 2010; 10(1):29-35. PubMed ID: 20104932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
    Dick RJ; Dear AE; Byron KA
    Heart Lung Circ; 2011 Oct; 20(10):657-8. PubMed ID: 21215696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
    JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.
    Geisler T; Schaeffeler E; Dippon J; Winter S; Buse V; Bischofs C; Zuern C; Moerike K; Gawaz M; Schwab M
    Pharmacogenomics; 2008 Sep; 9(9):1251-9. PubMed ID: 18781853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to antiplatelet treatment: from genes to outcome.
    Giusti B; Abbate R
    Lancet; 2010 Oct; 376(9749):1278-81. PubMed ID: 20801497
    [No Abstract]   [Full Text] [Related]  

  • 35. CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention.
    Zou JJ; Chen SL; Fan HW; Tan J; He BS; Xie HG
    J Cardiovasc Pharmacol; 2014 Feb; 63(2):178-83. PubMed ID: 24508947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
    Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
    Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
    Xie X; Ma YT; Yang YN; Li XM; Ma X; Fu ZY; Zheng YY; Chen BD; Liu F
    PLoS One; 2013; 8(3):e59344. PubMed ID: 23555019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.
    Lee JM; Park S; Shin DJ; Choi D; Shim CY; Ko YG; Kim JS; Shin ES; Chang CW; Lee JE; Jang Y
    Am J Cardiol; 2009 Jul; 104(1):46-51. PubMed ID: 19576320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.